194 results on '"Ly, Quan P."'
Search Results
2. Mucins as contrast agent targets for fluorescence-guided surgery of pancreatic cancer.
3. Author Correction: Cancer-associated fibroblast-derived acetate promotes pancreatic cancer development by altering polyamine metabolism via the ACSS2–SP1–SAT1 axis
4. Mucins as contrast agent targets for fluorescence-guided surgery of pancreatic cancer
5. Pancreatic Tumor Microenvironment Factor Promotes Cancer Stemness via SPP1–CD44 Axis
6. Metastatic Giant Cell Tumor Causing Small Bowel Intussusception on 18F-FDG PET/CT
7. Abstract C008: MUC16 expression in pancreatic ductal adenocarcinoma patient samples after neoadjuvant chemotherapy
8. Selective inhibition of stemness through EGFR/FOXA2/SOX9 axis reduces pancreatic cancer metastasis
9. Management of asymptomatic, well-differentiated PNETs: results of the Delphi consensus process of the Americas Hepato-Pancreato-Biliary Association
10. Phase I trial of concurrent stereotactic body radiotherapy and nelfinavir for locally advanced borderline or unresectable pancreatic adenocarcinoma
11. Indocyanine green loaded hyaluronan-derived nanoparticles for fluorescence-enhanced surgical imaging of pancreatic cancer
12. Fluorescence Guidance in Surgical Oncology: Challenges, Opportunities, and Translation
13. Dosimetric parameters correlate with duodenal histopathologic damage after stereotactic body radiotherapy for pancreatic cancer: Secondary analysis of a prospective clinical trial
14. Supplementary Figure S1 from Development of a MUC16-Targeted Near-Infrared Fluorescent Antibody Conjugate for Intraoperative Imaging of Pancreatic Cancer
15. Supplementary Video S1 from Development of a MUC16-Targeted Near-Infrared Fluorescent Antibody Conjugate for Intraoperative Imaging of Pancreatic Cancer
16. Data from Development of a MUC16-Targeted Near-Infrared Fluorescent Antibody Conjugate for Intraoperative Imaging of Pancreatic Cancer
17. Supplementary Data Summary from Development of a MUC16-Targeted Near-Infrared Fluorescent Antibody Conjugate for Intraoperative Imaging of Pancreatic Cancer
18. Esophageal and Esophagogastric Junction Cancers, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology
19. Phase I/II Trial of Neoadjuvant Oregovomab-based Chemoimmunotherapy Followed by Stereotactic Body Radiotherapy and Nelfinavir For Locally Advanced Pancreatic Adenocarcinoma
20. Acute Colonic Obstruction
21. Clinical Relevance of Targeted Interference with Src-Mediated Signal Transduction Events
22. Preclinical Evaluation of a Humanized, Near-Infrared Fluorescent Antibody for Fluorescence-Guided Surgery of MUC16-Expressing Pancreatic Cancer
23. Splenic and PB immune recovery in neoadjuvant treated gastrointestinal cancer patients
24. Su1675: ROLE OF NUMBER AND SIZE OF NERVES INVOLVED BY PANCREATIC ADENOCARCINOMA IN PREDICTING RECURRENCE AND SURVIVAL
25. Gastric Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology
26. Correction: Kaushal et al. Repurposing Niclosamide for Targeting Pancreatic Cancer by Inhibiting Hh/Gli Non-Canonical Axis of Gsk3β. Cancers 2021, 13, 3105
27. A Preoperative Nomogram to Predict the Risk of Perioperative Mortality Following Gastric Resections for Malignancy
28. Repurposing Niclosamide for Targeting Pancreatic Cancer by Inhibiting Hh/Gli Non-Canonical Axis of Gsk3β
29. Human splenic myeloid derived suppressor cells: Phenotypic and clustering analysis
30. Axillary Recurrence Rate Following Negative Sentinel Node Biopsy for Invasive Breast Cancer: Long-Term Follow-Up
31. Pre-operative Nomogram to Predict Risk of Peri-operative Mortality following Liver Resections for Malignancy
32. Erratum to: Axillary Recurrence Rate Following Negative Sentinel Node Biopsy for Invasive Breast Cancer: Long-Term Follow-Up
33. Survival Outcomes in Node-Negative Breast Cancer Patients Evaluated With Complete Axillary Node Dissection Versus Sentinel Lymph Node Biopsy
34. Selective inhibition of stemness through EGFR/FOXA2/SOX9 axis reduces pancreatic cancer metastasis
35. Comparative phenotypes of peripheral blood and spleen cells from cancer patients
36. Development of a MUC16-Targeted Near-Infrared Fluorescent Antibody Conjugate for Intraoperative Imaging of Pancreatic Cancer
37. CXCR2 signaling promotes secretory cancer‐associated fibroblasts in pancreatic ductal adenocarcinoma
38. MUC16 as a potential target for the surgical detection of pancreatic cancer
39. Tuned near infrared fluorescent hyaluronic acid conjugates for delivery to pancreatic cancer for intraoperative imaging
40. Melanoma and Nonmelanoma Skin Cancer
41. Contributors
42. Management of the primary tumor in patients with metastatic pancreatic neuroendocrine tumor: a contemporary single-institution review
43. Selective Inhibition of Histone Deacetylases 1/2/6 in Combination with Gemcitabine: A Promising Combination for Pancreatic Cancer Therapy
44. Esophageal and Esophagogastric Junction Cancers, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology
45. Abstract 1420: Novel expansion of CD8+PD1+ spleen cells for therapeutic intent in pancreatic adenocarcinoma cancer
46. Surgical imaging of pancreatic cancer using polysaccharide-delivered near infrared fluorophores
47. Thrombospondin-1 Promotes Proliferative Healing through Stabilization of PDGF
48. Fluorescence Guidance in Surgical Oncology: Challenges, Opportunities, and Translation
49. A phase II study of neodjuvant chemoimmunotherapy followed by stereotactic radiotherapy/nelfinavir in patients with locally advanced CA125 expressing pancreatic adenocarcinoma.
50. MUC1 and HIF-1alpha Signaling Crosstalk Induces Anabolic Glucose Metabolism to Impart Gemcitabine Resistance to Pancreatic Cancer
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.